Trials / Completed
CompletedNCT03414034
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Cardiff Oncology · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Onvansertib | Onvansertib orally |
| DRUG | Abiraterone | Abiraterone orally |
| DRUG | Prednisone | Prednisone orally |
Timeline
- Start date
- 2018-08-14
- Primary completion
- 2023-10-16
- Completion
- 2023-10-16
- First posted
- 2018-01-29
- Last updated
- 2024-11-07
- Results posted
- 2024-11-07
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03414034. Inclusion in this directory is not an endorsement.